Literature DB >> 9327251

Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE).

M A Pfaller1, R N Jones, S A Marshall, S L Coffman, R J Hollis, M B Edmond, R P Wenzel.   

Abstract

A surveillance study of nosocomial blood stream infections [Surveillance and Control of Pathogens of Epidemiologic Importance (SCOPE)] was conducted during a 14-month period in 1995 to 1996 in approximately 50 American medical centers. Among the 4725 blood stream infections, the etiologic agent was Enterobacter spp. in 230, Citrobacter freundii in 24, and Serratia marcescens in 65. The vast majority of these isolates (89%) had been sent to the University of Iowa including 198 Enterobacter spp. (46 Enterobacter aerogenes, 141 Enterobacter cloacae, 11 other Enterobacter spp.), 23 C. freundii, and 62 S. marcescens. Because these species are capable of producing Amp C beta-lactamase, we examined their susceptibility to 12 broad-spectrum antimicrobial agents. The frequency of resistance to ceftazidime and the molecular epidemiology of ceftazidime-resistant strains was also examined. Among the Enterobacter spp. and C. freundii isolates, resistance to third generation cephalosporins (ceftazidime, ceftriaxone) and broad-spectrum semisynthetic penicillins (piperacillin), with or without an enzyme inhibitor (piperacillin/tazobactam), was high, e.g., 35 to 50%. The S. marcescens isolates were quite susceptible to all agents tested. Both imipenem and cefepime were active against virtually all isolates tested including 84 stably derepressed Amp C-producing ceftazidime-resistant strains of Enterobacter spp. and C. freundii. The overall rank order of activity for the six best agents against these Amp C-producing strains was: imipenem (100% susceptible) > amikacin = cefepime (98.6%) > ciprofloxacin = gentamicin = ofloxacin (93.6 to 94.0%). Molecular typing studies of ceftazidime-resistant E. cloacae using an automated ribotyping system, as well as pulsed-field gel electrophoresis, indicated that although clonal spread of a single strain occurred in some of the medical centers, most of the episodes of bacteremia were caused by patient-unique strains. Control of these resistant organisms will require attention to microbiologic recognition of phenotypes, to infection control practices, and to limiting the overuse of certain extended spectrum beta-lactams.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9327251     DOI: 10.1016/s0732-8893(97)00064-3

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  29 in total

1.  Role of global surveillance in combating bacterial resistance.

Authors:  A Marchese; G C Schito
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Impact of Antibiotic Resistance on the Treatment of Gram-negative Sepsis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

3.  Extended-spectrum beta-lactamases in Ireland, including a novel enzyme, TEM-102.

Authors:  Dearbháile Morris; Colette O'Hare; Maura Glennon; Majella Maher; Geraldine Corbett-Feeney; Martin Cormican
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

4.  Efficacies of cefepime, ceftazidime, and imipenem alone or in combination with amikacin in rats with experimental pneumonia due to ceftazidime-susceptible or -resistant Enterobacter cloacae strains.

Authors:  O Mimoz; A Jacolot; S Leotard; N Hidri; K Samii; P Nordmann; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

Review 5.  A Primer on AmpC β-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World.

Authors:  Pranita D Tamma; Yohei Doi; Robert A Bonomo; J Kristie Johnson; Patricia J Simner
Journal:  Clin Infect Dis       Date:  2019-09-27       Impact factor: 9.079

6.  Impact of healthcare-associated acquisition on community-onset Gram-negative bloodstream infection: a population-based study: healthcare-associated Gram-negative BSI.

Authors:  M N Al-Hasan; J E Eckel-Passow; L M Baddour
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-08       Impact factor: 3.267

7.  Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998.

Authors:  M A Pfaller; R N Jones; G V Doern; H S Sader; S A Messer; A Houston; S Coffman; R J Hollis
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

Review 8.  Clinical role of beta-lactam/beta-lactamase inhibitor combinations.

Authors:  Nelson Lee; Kwok-Yung Yuen; Cyrus R Kumana
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Epidemiological risk factors for isolation of ceftriaxone-resistant versus -susceptible citrobacter freundii in hospitalized patients.

Authors:  Peter W Kim; Anthony D Harris; Mary-Claire Roghmann; J Glenn Morris; Arjun Strinivasan; Eli N Perencevich
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

10.  Characterization of ESBL (SHV-12) producing clinical isolate of Enterobacter aerogenes from a tertiary care hospital in Nigeria.

Authors:  Murat Kasap; Kayode Fashae; Sinem Torol; Fetiye Kolayli; Fatma Budak; Haluk Vahaboglu
Journal:  Ann Clin Microbiol Antimicrob       Date:  2010-01-12       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.